Alcon gets FDA approval for injectable ophthalmic corticosteroid Triesence |
|
|
|
Published
:
Fri, 30 Nov 2007 23:30 |
SAN FRANCISCO (Thomson Financial) - Alcon Inc. said late Friday the Federal Drug Administration has approved Triesence 40 mg/mL, an injectable synthetic corticosteroid used in treating ophthalmic conditions unresponsive to topical corticosteroids.The active ingredient in Triesence, triamcinolone acetonide, has been used for many years to treat retinal disease, Alcon said.Shares of the Swiss eyecare company closed the regular session up $2.97 at $139.14.Brigid Gaffikinbg/gmCOPYRIGHTCopyright Thomson Financial News Limited 2007. All rights reserved.The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
|
|
|
|